Cutaneous involvement in dermatomyositis can be the prevalent component of disease, failing to respond to adequate therapies for myositis. In this case report, we describe a patient affected by dermatomyositis, characterized by prevalent skin involvement, successfully treated with Staphylococcus protein A-based extracorporeal immunoadsorption (Immunosorba, Fresenius Medical Care AG & Co. KGaA, Bad Homburg, Germany) and thalidomide. The patient showed panniculitic ulcerative lesions of the skin, difficult to treat because of side effects or ineffectiveness of various therapies. Skin manifestations rapidly improved after introduction of immunoadsorption; The association of thalidomide allowed a good maintenance of these results until the remission of skin lesions, despite several infective complications of some residual ulcers. Considering the difficulties in the management of our patient, combined therapy with Immunosorba and thalidomide has allowed a good clinical response. If confirmed, the observed beneficial effects suggest that protein A-based immunoadsorption and thalidomide can represent an alternative option in dermatomyositis, especially when cutaneous manifestations are predominant

Staphylococcus protein A-based extracorporeal immunoadsorption and thalidomide in the treatment of skin manifestation of dermatomyositis: a case report / Sebastiani, Marco; R., Puccini; Manfredi, Andreina Teresa; E., Manni; Colaci, Michele; P., Mattei; P., Barachini; Ferri, Clodoveo. - In: THERAPEUTIC APHERESIS AND DIALYSIS. - ISSN 1744-9979. - STAMPA. - 13:3(2009), pp. 225-228. [10.1111/j.1744-9987.2009.00689.x]

Staphylococcus protein A-based extracorporeal immunoadsorption and thalidomide in the treatment of skin manifestation of dermatomyositis: a case report.

SEBASTIANI, Marco;MANFREDI, Andreina Teresa;COLACI, Michele;FERRI, Clodoveo
2009

Abstract

Cutaneous involvement in dermatomyositis can be the prevalent component of disease, failing to respond to adequate therapies for myositis. In this case report, we describe a patient affected by dermatomyositis, characterized by prevalent skin involvement, successfully treated with Staphylococcus protein A-based extracorporeal immunoadsorption (Immunosorba, Fresenius Medical Care AG & Co. KGaA, Bad Homburg, Germany) and thalidomide. The patient showed panniculitic ulcerative lesions of the skin, difficult to treat because of side effects or ineffectiveness of various therapies. Skin manifestations rapidly improved after introduction of immunoadsorption; The association of thalidomide allowed a good maintenance of these results until the remission of skin lesions, despite several infective complications of some residual ulcers. Considering the difficulties in the management of our patient, combined therapy with Immunosorba and thalidomide has allowed a good clinical response. If confirmed, the observed beneficial effects suggest that protein A-based immunoadsorption and thalidomide can represent an alternative option in dermatomyositis, especially when cutaneous manifestations are predominant
2009
13
3
225
228
Staphylococcus protein A-based extracorporeal immunoadsorption and thalidomide in the treatment of skin manifestation of dermatomyositis: a case report / Sebastiani, Marco; R., Puccini; Manfredi, Andreina Teresa; E., Manni; Colaci, Michele; P., Mattei; P., Barachini; Ferri, Clodoveo. - In: THERAPEUTIC APHERESIS AND DIALYSIS. - ISSN 1744-9979. - STAMPA. - 13:3(2009), pp. 225-228. [10.1111/j.1744-9987.2009.00689.x]
Sebastiani, Marco; R., Puccini; Manfredi, Andreina Teresa; E., Manni; Colaci, Michele; P., Mattei; P., Barachini; Ferri, Clodoveo
File in questo prodotto:
File Dimensione Formato  
Sebastiani M et al SpA immunoadsorption and thalidomide in DM.pdf

Solo gestori archivio

Tipologia: Versione pubblicata dall'editore
Dimensione 167.88 kB
Formato Adobe PDF
167.88 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/645582
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 7
  • ???jsp.display-item.citation.isi??? 6
social impact